Heidelberg Pharma Publishes Article on Chemical Amanitin Synthesis in Angewandte Chemie Journal
- Chemical synthesis of the natural compound Amanitin successfully established by Heidelberg Pharma
- New, additional synthetic route suitable for larger-scale Amanitin production
- Patents and exclusive licenses to synthetic routes protect Heidelberg Pharma’s ATAC technology
Heidelberg Pharma AG today announced that a scientific article on the chemical synthesis of the fungal compound Amanitin has been published in Angewandte Chemie, a leading chemical journal. In this article, researchers from Group subsidiary Heidelberg Pharma Research GmbH describe a novel, scalable synthetic process for the mushroom toxin Amanitin, which was developed in the laboratories of Heidelberg Pharma Research. To the Company’s knowledge, Heidelberg Pharma Research is the first company together with its production partner Carbogen AMCIS AG, Bubendorf, Switzerland, to have succeeded in synthetically producing Amanitin in GMP in the gram range based on this synthesis process. The summary of this article is available at https://onlinelibrary.wiley.com/doi/abs/10.1002/anie.201914935?af=R.